BioNTech and Pfizer unveiled promising early-stage results for BNT327, a bispecific antibody designed to tackle advanced non-small cell lung cancer through a novel two-pronged mechanism. Presented at ASCO 2026, the experimental therapy simultaneously targets PD-L1 immune suppression and VEGF-A-driven angiogenesis, addressing a critical limitation of conventional single-agent immunotherapies. The Phase I dose-escalation trial enrolled 45 patients with advanced NSCLC who had exhausted standard treatment options. Notably, BNT327 achieved disease control in 67% of heavily pretreated patients, with response rates varying by treatment line: 78% in second-line patients, 67% in third-line, and 52% in fourth-line or beyond. Particularly encouraging, patients who had previously progressed on PD-1 inhibitors still responded to the bispecific approach, suggesting the dual-pathway strategy can overcome checkpoint inhibitor resistance. The FDA has designated BNT327 as a Fast Track therapy, potentially accelerating its path to clinical availability. Read the full article on GMJ Newsroom.
Was this article helpful?
